GE Medical Systems Functional Imaging features the world's most comprehensive range of high-performance nuclear and PET imaging systems designed to help physicians optimize productivity and disease management while maximizing efficiency. Its offerings include a broad portfolio of diagnostic products, healthcare information systems, flexible financing, multi-vendor and biomedical service capability. Furthermore, Six Sigma quality resources, information technology, and comprehensive education programs, as well as a full-range of value-added services help to achieve the best possible return on investments, which results in better patient care and treatment.
Since 1976, GE has consistently been a pioneer in delivering new and innovative technologies to the nuclear medicine industry. Through cooperative ventures with leading luminary partners such as Emory University and Johns Hopkins University, GE continues to develop nuclear medicine software programs of the highest clinical utility.
With more than 10,000 nuclear medicine systems installed worldwide, GE Medical Systems holds the industry’s largest market share. Its' recent acquisitions of leading
companies such as Elscint and SMV and the ongoing development of single and dual-head gamma camera and computer technologies enable GE to offer the customer more innovative nuclear medicine solutions than ever before.
In the arena of dedicated PET, for years, physicians have talked about the benefits of fusing CT and PET images for improving patient diagnostic outcomes. Today, GE is the first and only company to offer an entire line of combined PET/CT products, the Discovery family, that enables physicians to see and treat cancer more effectively than ever before. The GE Discovery LS(tm) is our new, state-of-the-art PET/CT system that delivers a true hybrid image in half the time of traditional PET scanners, without repositioning the patient. Discovery LS combines the most sophisticated CT scanner available today, the GE LightSpeed(tm) Plus, with the most advanced PET system, the GE Advance NXi(tm). For patients who are suspected of having cancer, the GE Discovery LS allows doctors to significantly see the extent and disease location.
Looking towards the future, molecular imaging represents the cutting-edge of medical technology. GE Medical Systems is combining molecular imaging with applied genomics research to help detect and assess risk levels for diseases such as breast and prostate cancer. GE is teaming up with leaders in the area of novel contrast agents and proteomics to bring physicians new means of diagnosing disease and assessing risk before symptoms appear and without unnecessary exploratory procedures. GE Medical's non-invasive molecular imaging methods -- such as (PET) combined with (CT) or (MRI) combined with novel imaging agents -- are being developed to detect pre-symptomatic disease. At the same time, genetic and protein-based analysis systems are being developed to aid in defining and identifying patient populations at high risk for specific diseases. Linking imaging information with genetic and protein data will have the potential to help cancer professionals diagnose disease earlier, individualize treatment and confirm the effectiveness of treatment - nothing short of a revolution in health care delivery.
Only GE has such a complete offering of other imaging modalities, unmatched strength and stability, Six Sigma design processes, customer support, educational opportunities and other resources that help you gain the most from nuclear and PET imaging systems investment.
By using our site or downloading materials from the site, you agree to our Privacy Policy and Terms of Use. Click above to review those policies. If you do not agree, do not use the site or download any materials from it.
